FDA
-
-
-
-
-
-
-
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
-
-
-
-
-
-
-
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
-
-
-
-
-
-
-
Belite Bio ADR (BLTE) Reiterated at Buy by Benchmark After Model Update
-
-
-
-
-
-
-
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
-
-
-
-
-
-
-
Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE) Following PIPE Transaction
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Belite Bio, Inc, ADR (BLTE)
-
330,719 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

